Our Clients Are Our Priority

We represent local, national and international pharmaceutical and biotech companies, and we tailor our approach to each client's specific needs and goals.

Green Griffith is a preeminent intellectual property law firm, uniquely qualified to assist  pharmaceutical and biotech companies protect their most valuable assets and position them for future success. Our extensive experience, technical expertise, big picture vision and integrated strategy consistently produce favorable results for companies developing, protecting, and commercializing drugs and therapies. Our attorneys share decades of experience in partnering with both generic and brand companies, assisting them in navigating the most complex IP issues, including the Hatch-Waxman Act.

We represent local, national and international companies, from small startups to multinational businesses, and we tailor our approach to suit each client’s individual business needs and goals. We offer a full-service practice, helping clients acquire, manage, protect and enforce their intellectual property.

We focus on helping clients build effective IP strategies that secure market position, or overcome obstacles to new product entry--whether this requires litigation or pre-litigation planning (505(b)(2), ANDA), Inter Partes Reviews, assessment of FDA exclusivity issues, opinions or portfolio analysis/development.  Our technical knowledge makes the difference: all of our attorneys have degrees in pharma-related fields, including organic chemistry, chemical engineering and molecular biology, and many have advanced degrees.

We are committed to our clients and do what it takes to ensure their success. We are collaborative, proactive and strategic. We work as an extension of our client's team, making sure their needs are met. We partner with them to gain an understanding of their strategy, and then we help them refine and execute it. We value the trust and confidence our clients place in us. In return, we promise honesty, hard work and quality service.